Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Acurx Pharmaceuticals, Inc. ACXP
$3.03
-$0.22 (-7.34%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
36766170.00000000
-
week52high
4.85
-
week52low
2.33
-
Revenue
0
-
P/E TTM
-4
-
Beta
0.00000000
-
EPS
-1.11000000
-
Last Dividend
0.00000000
-
Next Earnings Date
16 мар 2023 г. в 12:00
Описание компании
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Buy | 29 ноя 2021 г. | |
| Alliance Global Partners | Buy | 10 янв 2023 г. | |
| HC Wainwright & Co. | Buy | 19 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| LUCI DAVID P | A | 19737 | 19737 | 27 июл 2022 г. |
| LUCI DAVID P | A | 1028460 | 19737 | 27 июл 2022 г. |
| DELUCCIA ROBERT J | A | 19737 | 19737 | 27 июл 2022 г. |
| DELUCCIA ROBERT J | A | 1051198 | 19737 | 27 июл 2022 г. |
| Sailer Carl | A | 19737 | 19737 | 27 июл 2022 г. |
| Sailer Carl | A | 92815 | 19737 | 27 июл 2022 г. |
| Sailer Carl | A | 73078 | 5161 | 23 ноя 2021 г. |
| LUCI DAVID P | A | 1008723 | 5200 | 19 ноя 2021 г. |
| DELUCCIA ROBERT J | A | 1031461 | 5034 | 19 ноя 2021 г. |
| Scodari Joseph C | A | 50000 | 50000 | 01 июл 2021 г. |
Новостная лента
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023
PRNewsWire
16 янв 2023 г. в 08:01
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive question and answer session at the Emerging Growth Conference STATEN ISLAND, N.Y. , Jan. 16, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, is pleased to announce that it has been invited to present at the Emerging Growth Conference on January 25, 2023.
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2022 Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 11:14
Start Time: 08:30 January 1, 0000 8:49 AM ET Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q3 2022 Earnings Conference Call November 14, 2022, 08:30 AM ET Company Participants David Luci - President and CEO Robert Shawah - Co-Founder and CFO Conference Call Participants Jason McCarthy - Maxim Group Operator Greetings. Welcome to Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022.
Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update
PRNewsWire
01 ноя 2022 г. в 08:01
STATEN ISLAND, N.Y. , Nov. 1, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 third quarter financial results on Monday, November 14, 2022, at 8:30 am ET before the U.S. financial markets open.
Acurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
16 авг 2022 г. в 11:53
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q2 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Robert Shawah - CFO David Luci - CEO Conference Call Participants Jim Molloy - Alliance Global Partners Operator Greetings. Welcome to Acurx Pharmaceuticals' Second Quarter 2022 Results and Business Update.
Acurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update
PRNewsWire
04 авг 2022 г. в 08:01
STATEN ISLAND, N.Y. , Aug. 4, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 second quarter financial results on Tuesday, August 16, 2022, at 8:30 am ET before the U.S. financial markets open.